High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience

High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience

Bibliographic Details
Main Authors:	Carlo Pietro Soatti, Durim Delishaj, Romerai D’Amico, Cristina Frigerio, Ilaria Costanza Fumagalli, Francesco Bonsignore, Giulia Sangalli, Fausto Declich, Stefano Arcangeli, Antonio Ardizzoia, Alessandro Colombo
Format:	Article
Language:	English
Published:	Termedia Publishing House 2020-12-01
Series:	Journal of Contemporary Brachytherapy
Subjects:	high-dose-rate brachytherapy prostate cancer prostate-specific antigen psa
Online Access:	https://www.termedia.pl/High-dose-rate-brachytherapy-as-monotherapy-for-localized-prostate-cancer-using-three-different-doses-14-years-of-single-centre-experience,54,42674,1,1.html

Similar Items

Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results
by: Durim Delishaj, et al.
Published: (2018-11-01)

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy
by: Kevin Martell, et al.
Published: (2017-04-01)

Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer
by: Marcin Miszczyk, et al.
Published: (2022-02-01)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
by: Tanaka Nobumichi, et al.
Published: (2012-09-01)

Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer
by: Jessika A. Contreras, et al.
Published: (2015-02-01)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
by: Hideyasu Tsumura, et al.
Published: (2016-04-01)

The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy
by: Wojciech M. Burchardt, et al.
Published: (2023-04-01)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
by: Justin Barnes, et al.
Published: (2019-07-01)

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer
by: Damián Guirado, et al.
Published: (2020-04-01)

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey
by: Susovan Banerjee, et al.
Published: (2023-12-01)

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
by: Bengt Johansson, et al.
Published: (2021-05-01)

Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results
by: Pedro J. Prada, et al.
Published: (2016-02-01)

Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis
by: Pieter Logghe, et al.

A review of whole gland prostate brachytherapy with focal dose escalation to intra-prostatic lesions: Clinical efficacy and technical aspects
by: Joel Poder, et al.
Published: (2024-10-01)

Dose differentiated high-dose-rate prostate brachytherapy: a feasibility assessment of MRI-guided dose escalation to dominant intra-prostatic lesions
by: Christopher Luminais, et al.
Published: (2022-10-01)

Evaluation of intraoperative magnetic resonance imaging/ultrasound fusion optimization for low-dose-rate prostate brachytherapy
by: Stephen Abel, et al.
Published: (2017-08-01)

Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer
by: Manabu Kato, et al.
Published: (2023-11-01)

Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer
by: Johan Staby Olsén, et al.
Published: (2025-03-01)

Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience
by: Justin Barnes, et al.
Published: (2019-10-01)

Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature
by: Durim Delishaj, et al.
Published: (2016-12-01)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
by: Hideya Yamazaki, et al.
Published: (2020-09-01)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
by: Pedro Galego, et al.
Published: (2015-04-01)

High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis
by: Eric M. Anderson, et al.
Published: (2021-08-01)

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
by: Ren Toriumi, et al.
Published: (2022-07-01)

Permanent <sup>125</sup>I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence
by: Mazeron Renaud, et al.
Published: (2012-03-01)

Challenge and Outcome for the Prostate Squamous Cell Carcinoma Which Developed 8 Years after Low-Dose-Rate Brachytherapy Approached by a Combined Multimodal Treatment with High-Dose-Rate Interstitial Brachytherapy, External Beam Radiation Therapy, and Chemotherapy
by: Toru Matsugasumi, et al.
Published: (2021-06-01)

Control charts for evaluation of quality of low-dose-rate brachytherapy for prostate cancer
by: Nicola J. Nasser, et al.
Published: (2022-08-01)

The Effect of Scattering from Leg Region on Organ Doses in Prostate Brachytherapy for 103Pd, 125I and 131Cs Seeds
by: Seyed Milad Vahabi, et al.
Published: (2016-09-01)

Image-guided high-dose-rate brachytherapy for prostate cancer patients with previous rectal resection and pelvic irradiation: feasibility study
by: Ewelina Gruszczynska, et al.
Published: (2019-06-01)

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate
by: Benjamin W. Fischer-Valuck, et al.
Published: (2019-12-01)

A preliminary study on rectal dose reduction associated with hyaluronic acid implantation in brachytherapy for prostate cancer
by: Tairo Kashihara, et al.
Published: (2024-04-01)

Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants
by: Wayne M. Butler, et al.
Published: (2021-04-01)

Template guided transperineal saturation biopsy of the prostate: lessons for focal and urethra-sparing high-dose-rate brachytherapy for localized prostate cancer
by: Sergey Nikolaevich Novikov, et al.
Published: (2016-04-01)

The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy
by: Michelle I. Echevarria, et al.
Published: (2016-11-01)

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up
by: Manuel Behmueller, et al.
Published: (2021-12-01)

Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer
by: Finbar Slevin, et al.
Published: (2020-12-01)

MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer
by: Cynthia Ménard, et al.
Published: (2022-08-01)

Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
by: Keisei Okamoto, et al.
Published: (2020-02-01)

Dosimetric Coverage of the Prostate, Normal Tissue Sparing, and Acute Toxicity with High-Dose-Rate Brachytherapy for Large Prostate Volumes
by: George Yang, et al.
Published: (2015-06-01)

Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning
by: Heloise Lavoie-Gagnon, et al.
Published: (2022-02-01)